CA3224527A1 — A pharmaceutical composition comprising combination of sglt2 inhibitor and dpp-iv inhibitor
Assigned to Unison Pharmaceuticals Pvt Ltd · Expires 2023-02-02 · 3y expired
What this patent protects
The present invention relates to a stable pharmaceutical composition comprising combination of a therapeutically effective amount of Sodium-glucose co-transporter-2 (SGLT2) inhibitor and a therapeutically effective amount of Dipeptidyl peptidase-4 (DPP4) inhibitor for reducing bl…
USPTO Abstract
The present invention relates to a stable pharmaceutical composition comprising combination of a therapeutically effective amount of Sodium-glucose co-transporter-2 (SGLT2) inhibitor and a therapeutically effective amount of Dipeptidyl peptidase-4 (DPP4) inhibitor for reducing blood glucose level in patients with diabetes. The present invention specifically relates to a stable pharmaceutical composition comprising Dapagliflozin or a pharmaceutically acceptable salts or solvates thereof, and Linagliptin or a pharmaceutically acceptable salts or solvates thereof in presence of one or more pharmaceutically acceptable excipients. Moreover, the present invention relates to a stable pharmaceutical composition comprising Dapagliflozin, Linagliptin and one or more pharmaceutically acceptable excipients with reduced degradation impurities.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.